Equivalency of Fecal Immunochemical Tests and Colonoscopy in Familial Colorectal Cancer Screening

详细信息    查看全文

• 作者：Enrique Quintero¹ ; ^&lowast ; ; ^{equinter@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Marta Carrillo¹ ; ^&lowast ; ; Antonio Z. Gimeno-Garc&iacute ; a¹ ; Manuel Herná ; ndez-Guerra¹ ; David Nicolá ; s-Pé ; rez¹ ; Inmaculada Alonso-Abreu¹ ; Maria Luisa D&iacute ; ez-Fuentes² ; V&iacute ; ctor Abraira³ ; ⁴
• 关键词：Familial Colorectal Cancer ; Colon Cancer ; Diagnostic Yield ; Colonoscopy Resources
• 刊名：Gastroenterology
• 出版年：2014
• 出版时间：November 2014
• 年：2014
• 卷：147
• 期：5
• 页码：1021-1030.e1
• 全文大小：798 K

文摘

Colonoscopy is the recommended screening procedure for first-degree relatives of patients with colorectal cancer (CRC), but few studies have compared its efficacy for CRC detection with that of other screening strategies. We conducted a controlled randomized trial to compare the efficacy of repeated fecal immunochemical tests (FITs) and colonoscopy in detecting advanced neoplasia (advanced adenoma or CRC) in family members of patients with CRC.

Methods

In a prospective study, 1918 first-degree relatives of patients with CRC were randomly assigned (1:1 ratio) to receive a single colonoscopy examination or 3 FITs (1/year for 3 years; OC-Sensor; cutoff ≥10 μg hemoglobin/g feces, corresponding to 50 ng hemoglobin/mL buffer). The strategies were considered to be equivalent if the 95% confidence interval of the difference for the detection of advanced neoplasia was ±3%. Follow-up analyses were performed to identify false-negative FIT results and interval CRCs.

Results

Of all eligible asymptomatic first-degree relatives, 782 were included in the colonoscopy group and 784 in the FIT group. In the intention-to-screen analysis, advanced neoplasia was detected in 33 (4.2%) and 44 (5.6%) first-degree relatives in the FIT and colonoscopy groups, respectively (odds ratio = 1.41; 95% confidence interval: 0.88–2.26; P = .14). In the per-protocol analysis, 28 first-degree relatives (3.9%) in the FIT group and 43 (5.8%) in the colonoscopy group had advanced neoplasia (odds ratio = 1.56; 95% confidence interval: 0.95–2.56; P = .08). FIT missed 16 of 41 advanced adenomas but no CRCs. The FIT strategy required endoscopic evaluation of 4-fold fewer individuals to detect 1 advanced neoplasia than the colonoscopy strategy.

Conclusions

Repeated FIT screening (1/year for 3 years) detected all CRCs and proved equivalent to colonoscopy in detecting advanced neoplasia in first-degree relatives of patients with CRC. This strategy should be considered for populations where compliance with FITs is higher than with colonoscopy. ClinicalTrials.gov number: NCT01075633 (COLONFAM Study).